Bicara Therapeutics Inc. (BCAX) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, and thank you for standing by. Welcome to the Bicara Therapeutics fourth quarter and full year twenty twenty five earnings call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you'll need to press 11 on your telephone. Please be advised today's conference is being recorded. I would now like to hand the conference over to your speaker today, Rachel Frank. Please go ahead. Thank you and good morning, everyone. It's a pleasure to welcome you to Bicara Therapeutics fourth quarter and full year twenty twenty five earnings call. Earlier this morning, we issued a press release highlighting results from the quarter and recent business progress. You can access the press release as well as the slides that we'll be reviewing today by going to the Investors section of our company website. Before we begin, please note that this call will include forward looking statements under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Please refer to our most recent SEC filings for important risk factors that could cause our actual performance and results to materially differ from those expressed or implied in these forward looking statements. Any forward looking statement made on this call represents our views only as of today, and we disclaim any obligation to update any forward looking statements. Joining us on the call today are Claire Mazumdar, Chief Executive Officer Brian Coleheat, President and Chief Operating Officer and Ivan Hyatt, Chief Financial Officer. I'll now turn the call over to Claire. Good morning, and welcome to Bicara Therapeutics Inc. I'm Claire Mazundar, Chief Executive Officer. Today marks an i...